Medical Condition News

RSS

Novel neuroprotective drug improves recovery after acute ischemic stroke

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48 hours of stroke symptoms, had better recovery than patients who received a placebo, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.

7 Feb 2026

Burn pit particles trigger lung inflammation through immune activation

A new study from National Jewish Health helps explain how exposure to burn pit smoke and desert dust may damage the lungs of military service members deployed to regions such as Afghanistan and Iraq.

7 Feb 2026

Optical tissue monitoring predicts dialysis-related fluid instability

For the millions of people living with end‑stage kidney disease, hemodialysis is more than a medical procedure, it is a thrice‑weekly lifeline that keeps the body's chemistry in balance.

7 Feb 2026

Moderate exercise lowers atrial fibrillation recurrence after ablation

New research from CU Anschutz scientists suggests that staying physically active after heart rhythm treatment may significantly reduce the risk of atrial fibrillation (AF) returning, offering patients a simple, low-cost way to support long-term heart health.

7 Feb 2026

Cholesterol transporter ABCA1 boosts macrophage-driven cancer immunity

In recent years, cancer researchers have made major breakthroughs by using the body's immune system to fight cancer. One of the most promising approaches, known as immune checkpoint blockade, works by releasing molecular "brakes" on T cells.

7 Feb 2026

Tumor-targeted chimeric drug increases efficacy and limits side effects

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more effectively.

7 Feb 2026

Water pressure mechanism enables fast amoeboid cancer cell movement

Cancer is one of the leading causes of death worldwide, marked by the uncontrolled growth of abnormal cells.

7 Feb 2026

RNA micelles enable targeted chemotherapy without immune toxicity

A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and other therapies directly to tumors, killing cancer cells without generating an immune response or toxicity-related side effects.

7 Feb 2026

Bioadhesive patches target remaining glioblastoma cells after surgery

Glioblastoma is the most prevalent and aggressive brain tumor. It proliferates very rapidly, is highly invasive, and there is currently no treatment capable of halting its progression or curing it, which means life expectancy after diagnosis is very short.

6 Feb 2026

Blocking p300 restores chemotherapy sensitivity in resistant tumors

Overcoming tumor resistance to chemotherapy drugs has long been a challenge for oncology clinicians and researchers.

6 Feb 2026

4D-printed vascular stents expand naturally at body temperature

Cardiovascular diseases constitute a major global health concern. Various complications that affect normal blood flow in arteries and veins, such as stroke, blood clot formation in veins, blood vessel rupture, and coronary artery disease, often require vascular treatments.

6 Feb 2026

Senescent neutrophils promote tumor survival across cancer types

Renowned as first responders to threatening infections, neutrophils also happen to feature prominently in the microenvironment of tumors, where they and other immune cells play opposing and frequently mutable roles in promoting-or resisting-cancer progression.

6 Feb 2026

European collaboration transforms immune cell data into cancer biomarkers

World Cancer Day, marked on 4 February, is an international day dedicated to raising awareness of cancer, and to encouraging its prevention, detection and treatment.

6 Feb 2026

Dementia collaborative care delivers greater value than Alzheimer’s medication

Programs that match caregivers with patient navigators yield better outcomes than Alzheimer's drug – but combining the two may be best.

6 Feb 2026

Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.

6 Feb 2026